
Opinion|Videos|December 6, 2024
Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy
Key Takeaways
- Early and aggressive treatment strategies are crucial for improving outcomes in high-risk metastatic castration-sensitive prostate cancer.
- Combining androgen deprivation therapy with novel hormonal agents or chemotherapy enhances survival rates.
Panelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Finally, to close out, which clinical pearls would you like to share with other health care providers who treat patients with high-risk metastatic castration-sensitive prostate cancer?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial
2
The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD
3
Can Aydogdu, MD on using ctDNA to predict nodal metastases at cystectomy
4
KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM
5








